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100 Poster Session-IIand PFS (p 5 0.05). On multivariate analysis, pts who were in
‘‘marrow remission’’ and had adverse cytogenetics had a signifi-
cantly higher rate of disease progression (p\0.001), lower OS
(p\0.001), and lower PFS (p\0.001). De novo AML was associ-
ated with a significantly better OS and PFS. Cytogenetics and
remission status are significant predictors for outcomes after
alloSCT in pts with AML or MDS.273
A STRATEGY FOR REDUCING CD31 CONTENT OF PERIPHERAL BLOOD
PROGENITOR CELL PRODUCTS FOR MATCHED RELATED DONOR ALLO-
GRAFTS
Racquel, I.-S.D., Khaleel, A., Arabella, T., Larry, L., William, V.P.,
Donna, S.E. University of Alabama, Birmingham, AL
Acute GVHD (aGVHD) causes significant morbidity and mor-
tality after allogeneic stem cell transplantation. Stem cells col-
lected from the peripheral blood (PBSC) provide greater ease of
cell collection and faster engraftment vs marrow source stem cells.
The association of PBSC with faster engraftment is likely due to
a higher number of committed precursors in the PBSC product.
Unfortunately, PBSC grafts are associated with an increased inci-
dence and severity of aGVHD due to higher numbers of alloreac-
tive T cells. Compensatory survival benefit of the larger CD31
content in PBSC collections resulting from graft vs malignancy ef-
fect has been difficult to demonstrate, however significant ‘‘purg-
ing’’ of CD31 cells below the CD31 content of marrow source
allograft results in engraftment failure, and disease relapse. We
hypothesize that reducing CD31 cell content of PBSC grafts
that of marrow source grafts would decrease the incidence of
aGVHD without compromising engraftment. We recently re-
ported a retrospective analysis of 98 patients who received
PBSC product purged of T cells in vivo by the administration of
dexamethasone to the donor for the last 3 days of G CSF mobili-
zation. The mean CD31 and CD341 cells collected were 3.68 
108 cells/kg (sd5 2.27 108) and 8.82 106 cells/kg (sd5 5.05
106) respectively. All patients engrafted successfully and had less
acute GVHD than historical controls (19% grade II–IV at 100
days). Updated data includes 41 additional patients who achieved
comparable T cell depletion with a mean CD31 content of 3.38
107 cells/kg (sd 5 2.19  107) and mean CD 341 content of
6.98  106 cells/kg (standard deviation of 4.05  106). However,
like almost all previous studies, the CD31 content of the grafts
is highly variable. We are now conducting a phase II non-random-
ized trial under an IDE from the FDA standardizing the T cell
content of the donor PBSC product to 2.5 60.5  10 7 cells/kg,
the concentration found in marrow collections. After setting aside
a portion of the PBSC product containing 2.5 60.5  107, the re-
maining product is CD31 cell depleted using magnetic bead cell
sorting technology. This allows us to study the influence of CD31
subsets, NK cells, and other graft components in engraftment, im-
mune reconstitution, and GVHD risk. Ultimately the goal of
standardization is to create a platform for ‘‘add back’’ research
and permitting a prescriptive approach to optimizing graft
content for different clinical situations.274
PERSONALIZED DOSING OF CYCLOPHOSPHAMIDE IN THE TOTAL
BODY IRRADIATION-CYCLOPHOSPHAMIDE CONDITIONING REGIMEN:
A PHASE II TRIAL IN PATIENTS WITH HEMATOLOGIC MALIGNANCY
McDonald, G.B., Guthrie, K.A., Batchelder, A., Witherspoon, R.,
McCune, J.S. Fred Hutchinson Cancer Research Center, Seattle, WA
Total body irradiation and cyclophosphamide (CY) conditioning
may cause regimen-related toxicity and mortality because of highly
variable metabolism of CY. The metabolite carboxyethylphosphor-
amide mustard (CEPM) is a reporter molecule for toxins derived
from CY. We tested the hypothesis that personalized CY dosing
would result in less liver and kidney toxicity, compared to
weight-based CY dosing (2  60 mg/kg), without affecting the
relapse rate.
Methods: We personalized the dose of CY for 50 patients receiv-
ing TBI 12 Gy using therapeutic drug monitoring with Bayesianparameter estimation after the first CY dose, to adjust the second
CY dose before allogeneic transplant (Clin Cancer Res
2006;12:4888–98). The target exposure to CEPM was 325 6 25
mM$hr. Concurrent allograft patients (N 5 100) who were condi-
tioned with TBI 12 Gy and CY 120 mg/kg served as controls.
Study endpoints were peak bilirubin levels, acute kidney injury
(doubling baseline Cr), and relapse/survival using proportional
hazards regression models.
Results: All patients on a personalized CY dosing protocol
received a first CY dose of 45 mg/kg. The mean second CY dose
was 66 mg/kg (range, 0–100 mg/kg), and the mean total CY dose
was 111 mg/kg (range, 45–145 mg/kg). There were 15 patients
whose total CY dose exceeded 120 mg/kg. The mean total AUC-
CEPM was 302 mM$hr (median 301, range 136–442 mM$hr).
The average percent deviation of the observed AUC-CEPM
from our target of 325 mM$hr was -7%. Peak total bilirubin was
significantly lower with personalized CY dosing than with stan-
dard dosing (median 1.3 mg/dL, range 0.7 – 8.8) vs. 1.7 mg/dL,
range 0.4 – 18.3), p 5 0.03. The hazard of kidney injury was re-
duced by 38% with personalized CY dosing (p 5 0.03); high bili-
rubin levels were associated with kidney injury (p 5 0.003).
Despite a lower total CY dose for most patients, personalized
CY dosing was not associated with worse relapse or survival out-
comes for the study cohort as a whole, or when analyzed as sub-
groups (by myeloid vs. lymphoid malignancy and by risk of
relapse after transplant).
Conclusions: Bayesian therapeutic drug monitoring and person-
alized CY dosing reduces extreme variability in CY metabolism in
the TBI/CY regimen, resulting in less liver and kidney injury,
compared to standard CY dosing, with no difference in relapse or
survival.275
PROSPECTIVE RANDOMIZED STUDY COMPARING NON MYELOABLA-
TIVE (FLU-TBI) AND REDUCED INTENSITY (FLU-BU-ATG) CONDITION-
ING FOR HEMATOLOGICAL MALIGNANCIES: A MULTICENTER ITAC
STUDY
Blaise, D.1, Furst, S.1, Bay, J.O.2, Faucher, C.1, Michallet, M.3,
Boiron, J.M.4, Cahn, J.Y.5, Mohty, M.6 1 Institut Paoli-Calmettes, Mar-
seille, France; 2Centre Jean Perrin, Clermont Ferrand, France; 3Hopital
Edouard Herriot, Lyon, France; 4EFS Aquitaine Limousin, Bordeaux,
France; 5CHU, Grenoble, France; 6Hotel Dieu, Nantes, France
Reduced intensity conditionings (RIC) have been introduced 10
years ago. However no definitive data exist defining the optimal
myeloablative and/or immunosuppressive association. We report
the first prospective comparison between 2 popular regimens based
on reduced intensity or non-myeloablative approaches. Flu-
Bu-ATG (Study A) associated Fludarabine (30mg/m2/5 days),
Oral Busulfan (8 mg/kg over 2 days) and Thymoglobuline (2.5
mg/m2/1day). Fluda-TBI (Study B) consisted of Fludarabine
(25mg/m2/ 3 days) and 2 Gy TBI. This program included two ran-
domized phase 2 clinical trials according to a phase 2 selection de-
sign (Liu, 1993 and 2001). Primary endpoint was one-year overall
survival (OS). Stopping rules included excessive engraftment fail-
ure and transplant related mortality ratio. Inclusion criteria were
patients presenting a hematological malignancy, non eligible for
myeloablative allo SCT, aged between 18 and 65, with a suitable
HLA identical sibling. First patient was included in January
2003. A total of 144 patients were randomized, and 137 patients
(Group A: N 5 71; group B: N 5 66) were documented in the da-
tabase for this abstract. In all, groups were well balanced for patient
characteristics; Median age 55 (32–66); Male gender: 63%; Diag-
nosis: acute leukemia: 18%; NHL: 23%; MM: 41%; Others:
18%; Disease status: CR5 29%; PR and stable disease5 63%; re-
fractory disease: 8%. Graft failure were documented in 4 patients in
group B. Cumulative incidence (CI)of aGVHD and cGVHD were
respectively of 24.4% (Group A 29.5%; Group B 19.4%) and
75.2% (Group A 77.8%; Group B 72.5%). One year TRM CI
was 18% (11–25)(Group A: 22% (11–33): group B: 15% (6–24);
p 5 NS). Overall 56% patients were alive at time of abstract
(Group A: 49%; Group B: 62%: p 5NS) for a one-year OS prob-
ability estimate of 0.75 [0.66 – 0.82] (Group A 0.73 [0.59 – 0.82];
Group B 0.78 [0.64 – 0.86]). In conclusion, this study establishes
